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Purpose: To investigate programmed cell death-ligand 1 (PD-L1) expression status and
the clinical and pathological factors related to its expression in urothelial carcinoma
(UC) patients.
Materials and Methods: Data from 761 UC patients who underwent testing for PD-L1
expression using the VENTANA (SP-142 immunohistochemistry assay) for measuring
PD-L1 expression according to the manufacturer’s protocol between February 2016 and
July 2019 were retrospectively reviewed. Patients were categorized into three groups
based on the percentage of tumor area covered by PD-L1-expressing tumor-infiltrating
immune cells (ICs) as follows: IC0 (<1%), IC1 (≥1% and<5%), and IC2/3 (≥5%). Positive
PD-L1 expression was defined as IC2/3 (≥5%). The factors related to positive PD-L1
expression were assessed by using unadjusted and adjusted logistic regression analyses.
Results: In the entire cohort, 213 (28%) patients showed positive PD-L1
expression. Final adjusted regression analyses for positive PD-L1 expression revealed
that several factors, including intravesical BCG prior to PD-L1 testing (odds
ratio [OR] 0.57, 95% confidence interval [CI] 0.37–0.96), advanced tumor stage
(stage III/IV) (OR 2.04, 95% CI 1.41–2.93), and high tumor grade (OR 5.31,
95% CI 2.38–11.83) were significantly associated with positive PD-L1 expression.
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Conclusions: This study showed that the PD-L1 expression is associated with
several clinical and pathological factors for the first time in a real-world setting. Further
follow-up clinical trials should consider adjusting these factors, including intravesical BCG
treatment, tumor stage and grade to clarify the utility of PD-L1 as a biomarker.
Keywords: urothelial carcinoma, immune cell, programmed cell death-ligand 1, immunohistochemistry, immune
checkpoint
INTRODUCTION
Immune checkpoints, such as programmed cell death-1 (PD-
1) and its associated ligand (PD-L1), have attracted significant
attention as major protein targets for systemic immunotherapy
of a number of solid tumors, including urothelial carcinoma
(UC) (1). In the tumor microenvironment, tumor cells use
these immune checkpoints to evade immune system attack
by blocking T-cell function. Therefore, anti-tumor immunity
can be achieved by restoring T-cell function using antibodies
that inhibit the receptor-ligand interaction and block the
immune checkpoints (1). Considering the immunogenic features
of UC, there have been a number of clinical trials of
immune checkpoint inhibitors (ICI) for UC in recent years
(2–9). On the basis of the efficacy and safety identified in
these clinical trials, five PD-1(pembrolizumab, nivolumab)/PD-
L1(atezolizumab, durvalumab, and avelumab) inhibitors have
been recommended for first or second-line use in the
treatment of locally advanced or metastatic UC by international
guidelines (10).
However, approximately 70–80% of patients are unresponsive
to ICI (1). Therefore, biomarkers for patient response would
be useful for identifying the optimal patient population which
is most likely to benefit from treatment with ICI. Several
biomarker candidates have been explored in relation to ICI
therapy in UC (11–14). Among these, PD-L1 expression
has been suggested as a potential biomarker for predicting
the response to and prognosis following ICI therapy in
UC patients (2–9, 15–23). However, previous studies have
reported contradictory results, even with the same drug
and methodology. For example, the KEYNOTE-045 study
of pembrolizumab found no association between objective
response rate and combined positive score (CPS) for PD-
L1 expression, but the KEYNOTE-052 study did in first
line (2, 8).
To date, four distinct immunohistochemistry (IHC) assays
are available for measuring PD-L1 expression in UC (24–26).
There are disparities among the IHC assays for PD-L1 expression
in terms of the cell populations assayed (tumor cells [TCs] or
tumor-infiltrating immune cells [ICs]), the type of detection
antibodies used, and the cutoff values for scoring, making it
difficult to generalize their results (24–27). In addition, PD-
L1 expression test results can be affected by multiple factors,
including specimen size, biopsy location, timing of tissue
collection, and treatmentmodality (i.e., radiation, chemotherapy,
and intravesical instillation of bacillus Calmette–Guerin [BCG])
(11, 24–28).
In the present study, we aimed to identify the PD-L1
expression status using the VENTANA (SP142) test which
was used as a companion diagnostic test for atezolizumab in




This retrospective multicenter study’s protocol was approved by
the Institutional Review Board of each participating institution
(approval no. of corresponding author NCC-2019-0080). The
requirement for written informed consent was waived because
of the retrospective design. All patient data and records were
anonymized before the analysis. All study protocols were
complied with the principles of the Declaration of Helsinki.
We initially reviewed the medical records of patients with
UC histologically confirmed through a variety of surgical
procedures, such as transurethral resection (TUR), cystectomy,
nephroureterectomy or ureterectomy, and biopsy, between
February 2016 and July 2019 at nine institutions. Among these,
we included UC patients who received an IHC diagnostic
assay for PD-L1 expression and excluded those with pure
adenocarcinoma, pure squamous cell carcinoma and small
cell carcinoma.
IHC Assay for PD-L1 Expression
To avoid heterogeneities due to differences between IHC
diagnostic assays for PD-L1 expression (24–26), we only included
patients who received VENTANA testing, which uses SP142
as a detection antibody for measuring PD-L1 expression in
tumor-infiltrating ICs according to the manufacturer’s protocol.
It was originally designed to identify patients who are likely
to respond to atezolizumab treatment which, in the past, was
only reimbursed by the government for second line therapy in
metastatic UC in Korea based on the results of the VENTANA
test. In reference to previous reports on atezolizumab (3, 4, 9),
PD-L1 expression level was initially classified into the following
three groups based on the percentage of the tumor area covered
by PD-L1 expressing ICs as measured by the VENTANA SP142
IHC assay: IC0 (<1%), IC1 (≥1 and <5%), and IC2/3 (≥5%).
For subsequent analyses, PD-L1 expression was dichotomized as
positive (≥5%) or negative (<5%) using a 5% cutoff value. The
results were interpreted by the urologic pathologists belonging
to each institution after completion of special training proposed
by Roche.
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Acquisition and Definition of Variables
A number of variables evaluated at the time of tissue biopsy
were examined to identify any relationships with positive PD-
L1 expression. The clinical variables included in the analysis
were age (<70 vs. ≥70 years), sex, smoking status, the
presence or absence of intravesical treatments (mitomycin-
C, BCG) and systemic chemotherapy prior to PD-L1 testing,
and the presence or absence of metastasis at the diagnosis
of UC. PD-L1 assay-related variables included organ type
(lower tract, bladder or urethra/upper tract, renal pelvis or
ureter/metastatic site), operation type (TUR/cystectomy, radical
or partial/nephroureterectomy, or ureterectomy/biopsy for a
primary or metastatic lesion), pathologic tumor stage (stage
I/II/III/IV), pathologic tumor grade (low vs. high grade), and
time between tissue acquisition and PD-L1 testing (<1 vs. ≥1
month). Tumor stage and grade were assigned according to
the 2010 American Joint Committee on Cancer staging system
and the 2004 World Health organization system, respectively.
For efficient analysis, tumor stage was categorized into two
groups: organ confined (stage I/II) and non-organ confined
(stage III/IV) disease.
Statistical Analysis
Continuous variables are expressed as the median and
interquartile range (IQR) and categorical variables are expressed
as absolute numbers and relative percentages. The relationships
between the included variables and PD-L1 expression were
assessed using chi-squared test in the case of categorical
variables. The significant factors associated with positive PD-L1
expression were evaluated using unadjusted and adjusted logistic
regression analyses. All analyses were conducted with SPSS
version 21.0 (SPSS Inc., Chicago, IL, USA) and two-sided
P-values of <0.05 were considered to be statistically significant.
RESULTS
Baseline Characteristics of the Study
Population
A total of 761 UC patients consisting of between a minimum of
8 and a maximum of 297 subjects per institution were eligible for
analysis. Table 1 summarizes the distribution of the parameters
in the entire study cohort (n= 761) and each subgroup (negative
and positive PD-L1) divided based on the 5% cutoff value. The
study cohort had a median age of 70 (IQR: 62–77) and a male
predominance with a male to female ratio of approximately 4:1.
Intravesical chemotherapy and BCG treatments before PD-L1
testing were administered to 56 (7%) and 106 (14%) patients,
respectively. Of the patients, 266 (35%) presented withmetastases
to the lymph node only (17%) or to distant organs (18%) and 115
(15%) received systemic chemotherapy prior to PD-L1 testing.
500 (66%) and 261 (34%) patients showed organ confined (stage
I/II) and non-organ confined (stage III/IV) disease, respectively.
Most of the specimens for the PD-L1 testing were obtained from
lower tract (83%) including the bladder and surgical procedures
for UC of the bladder (82%; TUR, 55%; cystectomy, 27%). In the
entire cohort, a total of 213 (28%) patients showed positive PD-L1
expression (Table 1). The positive PD-L1 expression group had a
lower frequency of intravesical BCG before PD-L1 tesing, more
specimens obtained from cystectomy, more non-organ confined
disease, and higher tumor grade compared to the negative group
(all P-values < 0.05, listed in Table 1).
Factors Related to Positive PD-L1
Expression in UC Patients
When comparing the PD-L1 expression level between subgroups,
the rate of positive PD-L1 expression differed according to tumor
stage, tumor grade, and intravesical BCG treatment prior to PD-
L1 testing (Figure 1). Positive PD-L1 expression was frequently
observed in non-organ confined disease (stage III/IV), high
grade tumors, and in samples from patients without intravesical
BCG treatment before PD-L1 testing. Whereas, there were no
significant correlations between PD-L1 expression level and other
parameters, including age (as a binary variable), sex, metastatic
status, intravesical or systemic chemotherapy, organ type for PD-
L1 testing, and time from tissue acquisition to PD-L1 testing
(Figure 2).
To determine the related factors with positive PD-L1
expression, unadjusted and adjusted logistic regression analyses
using two separate models (including age as a continuous
or categorical variable) were performed (Table 2). The results
revealed that increased age (odds ratio [OR] 0.98, 95% confidence
interval [CI] 0.97–0.99), intravesical BCG prior to PD-L1 testing
(OR 0.57, 95% CI 0.34–0.96), upper tract origin (OR 0.49, 95%
CI 0.29–0.81), non-organ confined disease (OR 2.47, 95% CI
1.41–2.93), and high tumor grade (OR 5.31, 95% CI 2.38–11.83)
were the independent factors of positive PD-L1 expression.
In other words, several clinical factors, including younger
age, no intravesical BCG treatment prior to PD-L1 testing,
samples obtained from the lower urinary tract including the
bladder, advanced stage and high grade tumors, were significantly
associated with positive PD-L1 expression.
DISCUSSION
PD-L1 expression has been extensively studied to assess their
potential for predicting response to ICI therapy in metastatic UC.
In the phase II IMvigor210 trial, cohort 2 on atezolizumab for
second-line use, IC2/3 PD-L1 expression (defined as ≥5%) was
associated with a higher overall response rate of 26% compared
with 15% in all patients (4). This trend was also observed in
several ICI related clinical trials in metastatic UC (2, 5, 7).
However, results from other clinical trials showed no significant
correlation between PD-L1 expression and response to ICI in
patients with metastatic UC (3, 6, 8, 9). For example, data from
phase III trials, such as KEYNOTE-045 and IMvigor 211, showed
poor correlation of response to PD-1 and PD-L1 inhibitors with
PD-L1 status (8, 9). In addition to PD-L1, several biomarkers
such as tumor mutation burden, molecular subtyping, and
immune gene expression profile, have been extensively studied
as the factors that can help predict the response to ICI (11–
14, 28). Besides, it was recently reported that several clinical
factors, such as low neutrophil-to-lymphocyte ratio (<5) and
lack of visceral metastasis, may have predictive utility for clinical
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benefit, defined as any objective reduction in tumor size, to ICI
(29). These conflicting results describing the association between
PD-L1 expression and patient response may be attributed to the
heterogeneity of the four different IHC assays used for measuring
PD-L1 expression. First, clinical trials with pembrolizumab and
nivolumab use the Dako assay with the 22C3 and 28-8 detection
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FIGURE 1 | Comparison of PD-L1 expression in each subgroup. (A) Pathologic tumor stage (I/II vs. III/IV), (B) pathologic tumor grade (low vs. high), and (C)
intravesical BCG prior to VENTANA test (no vs. yes).
FIGURE 2 | Comparison of PD-L1 expression in each subgroup. (A) Age (<70 years vs. ≥70 years), (B) sex (male vs. female), (C) intravesical chemotherapy prior to
VENTANA (no vs. yes), (D) systemic chemotherapy prior to VENTANA (no vs. yes), (E) specimen acquisition site (lower tract vs. upper tract vs. metastatic site), (F)
time from tissue acquisition to VENTANA test (<1 month vs. ≥1 month), and (G) metastatic status (no vs. lymph node only vs. distant organ metastasis).
antibodies, respectively (12, 24, 25). On the other hand, clinical
trials with atezolizumab and durvalumab use the VENTANA
assay with SP142 and SP263 antibodies, respectively (12, 24,
25). Second, the cell populations assayed for scoring PD-L1
expression differ for each ICI (12, 24, 25). In the IMvigor trials
of atezolizumab, PD-L1 expression was scored using ICs (3, 4,
9), whereas the CheckMate trial for nivolumab used TCs to
score PD-L1 expression (6). Pembrolizumab, durvalumab, and
avelumab clinical trials scored PD-L1 expression using combined
TCs + ICs, CPS (5, 7, 8). Third, different cutoff values are
applied to define positive PD-L1 expression for each ICI. In
the case of atezolizumab, PD-L1 expression ≥5% was defined as
positive PD-L1 expression (3, 4, 9). The definition of positive
PD-L1 expression was PD-L1 ≥1% for nivolumab, ≥10% for
pembrolizumab, ≥25% for durvalumab, and ≥5% for avelumab
(5–8). In the end, the lack of IHC assay standardization can cause
variability in study results and hamper understanding of the role
of PD-L1 as a biomarker.
In this study, in an attempt to minimize the influence of
the heterogeneities between PD-L1 IHC assays, the VENTANA
test was selected as the only IHC assay for measuring PD-
L1 expression. Because the primary objective of this study
was to identify PD-L1 expression status in UC regardless of
atezolizumab use, UC specimens at all stages obtained through
a variety of surgical procedures were included in the analysis.
Generally, positive PD-L1 expression was observed in 28%
(213/761) of all UC patients, which is similar to previous
reports (15, 27). In particular, positive PD-L1 expression was
more common in non-organ confined stage III/IV disease (37%)
and high-grade tumors (31%) than in organ-confined stage I/II
disease (23%) and low grade tumors (7%). These correlations
between high PD-L1 expression and unfavorable pathological
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TABLE 2 | Unadjusted and adjusted logistic regression analyses for the related factors with positive PD-L1 expression.
Unadjusted analysis Adjusted analysis including Adjusted analysis including age
age as continuous variable as categorical variable
Variables Unadjusted OR (95% CI) P-value Adjusted OR (95% CI) P-value Adjusted OR (95% CI) P-value
Age (continuous) 0.98 (0.97–1.00) 0.05 0.98 (0.97–0.99) 0.04
Age (<70 vs. ≥70) 0.82 (0.60–1.12) 0.21 0.78 (0.56–1.09) 0.15
Sex (male vs. female) 0.77 (0.51–1.18) 0.23 0.66 (0.42–1.02) 0.06 0.67 (0.43–1.05) 0.08
Intravesical chemotherapy (no vs. yes) 0.94 (0.51–1.73) 0.83 1.61 (0.77–3.33) 0.20 1.59 (0.77–3.28) 0.21
Intravesical BCG (no vs. yes) 0.59 (0.36–0.99) 0.04 0.57 (0.34–0.96) 0.03 0.55 (0.33–0.94) 0.03
Systemic chemotherapy (no vs. yes) 1.33 (0.87–2.03) 0.19 1.14 (0.72–1.80) 0.57 1.14 (0.72–1.81) 0.56
Organ type (ref. lower tract)
Upper tract 0.76 (0.48–1.23) 0.26 0.49 (0.29–0.81) 0.006 0.48 (0.29–0.81) 0.006
Metastatic site 0.46 (0.13–1.59) 0.22 0.34 (0.09–1.22) 0.10 0.33 (0.09–1.21) 0.10
Stage (organ confined vs. non-organ confined) 1.96 (1.41–2.71) <0.01 2.04 (1.41–2.93) <0.01 2.00 (1.39–2.88) <0.01
Grade (low grade vs. high grade) 6.09 (2.78–13.36) <0.01 5.31 (2.38–11.83) <0.01 5.30 (2.38–11.80) <0.01
Time from tissue acquisition to VENTANA 1.10 (0.79–1.53) 0.58 0.89 (0.62–1.28) 0.53 0.89 (0.62–1.28) 0.54
(month) (<1 vs. ≥1)
PD-L1, programmed cell death-ligand 1; IC, immune cells; BCG, bacillus Calmette–Guerin.
features (advanced stage and high grade tumor) were also
identified in prior studies (15, 16). Meanwhile, positive PD-
L1 expression was more common in patients that had received
no intravesical BCG (29%) than in those that had (20%). This
finding contradicts previous studies, which reported higher PD-
L1 expression in BCG non-responders (including BCG relapsing
tumors) than in BCG responders in non-muscle invasive bladder
cancer (NMIBC) (30, 31). This discrepancy may be due to
a variety of reasons. First, a history of BCG therapy before
tissue acquisition for VENTANA does not necessarily indicate
BCG unresponsiveness. Second, unlike the previous studies,
which included only NMIBC patients, our study population
consisted of UC patients at all disease stages. In the subgroup
analysis of NMIBC patients only (n = 284), the positive PD-
L1 expression rate was not significantly different according
to BCG therapy (pre-BCG: 10%, post-BCG: 6%, P = 0.44,
Supplementary Figure 1), which is consistent with the result
from the previous study (31). As mentioned earlier, because PD-
L1 as a tumor marker has dynamic properties that are influenced
by various factors, we tried to evaluate the related factors for
PD-L1 expression. We found that advanced tumor stage (stage
III/IV), high tumor grade, younger age, no intravesical BCG, and
lower tract specimen significantly correlated with positive PD-
L1 expression. In summary, our study may provide meaningful
information on the overall aspects of PD-L1 expression and the
factors related to its expression in KoreanUC, which has not been
reported to date.
The current study has some limitations. First, there may
be inherent biases resulting from its multi-institutional and
retrospective features. For instance, there was no standardization
of the surgical procedures, including TUR, cystectomy,
nephroureterectomy and biopsy, which were performed
to obtain the UC specimens for the PD-L1 assays in each
institution. In addition, there were a different number of patients
from each institution, ranging from a minimum of 8 to a
maximum of 297 per institution. As a result, the data from
the institution enrolling the largest number of patients may
have had a stronger influence on the overall study results than
that from other institutions. However, these factors can also
be interpreted as strengths of this study because they reflect
real-world clinical experiences and help to generalize the results.
Finally, the present study considered PD-L1 expression in
UC of all stages, irrespective of ICI use. Thus, PD-L1 has not
been evaluated as a biomarker for predicting response to and
prognosis following ICI treatment. However, the study showed
that the rate of positive PD-L1 expression was significantly
higher in advanced stage and high-grade tumors, indicating that
PD-L1 expression may be also related to prognosis. To elucidate
this point, further follow-up studies will be needed to assess
the relationship between PD-L1 expression and response to
treatment and clinical outcomes for ICI therapy in the metastatic
UC setting.
CONCLUSION
Positive PD-L1 expression, defined as IC coverage ≥5% as
evaluated by the VENTANA test, was found in 28% of Korean
UC patients, and multiple factors, including younger age, no
intravesical BCG, lower tract specimen, advanced tumor stage,
and high-grade tumor correlated with positive PD-L1 expression.
To establish the utility of PD-L1 as a biomarker, further follow-up
clinical trials will be needed and should consider adjustment for
some factors, including intravesical BCG treatment, tumor stage,
and grade in the analysis.
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